The novel emerged SARS-CoV-2 has rapidly spread around the world causing acute infection of the respiratory tract (COVID-19) that can result in severe disease and lethality. For SARS-CoV-2 to enter cells, its surface glycoprotein spike (S) must be cleaved at two different sites by host cell proteases, which therefore represent potential drug targets. In the present study, we show that S can be cleaved by the proprotein convertase furin at the S1/S2 site and the transmembrane serine protease 2 (TMPRSS2) at the S2′ site. We demonstrate that TMPRSS2 is essential for activation of SARS-CoV-2 S in Calu-3 human airway epithelial cells through antisense-mediated knockdown of TMPRSS2 expression. Furthermore, SARS-CoV-2 replication was also strongly inhibited by the synthetic furin inhibitor MI-1851 in human airway cells. In contrast, inhibition of endosomal cathepsins by E64d did not affect virus replication. Combining various TMPRSS2 inhibitors with furin inhibitor MI-1851 produced more potent antiviral activity against SARS-CoV-2 than an equimolar amount of any single serine protease inhibitor. Therefore, this approach has considerable therapeutic potential for treatment of COVID-19.
Proteolytic cleavage of the influenza virus surface glycoprotein hemagglutinin (HA) by host cell proteases is crucial for infectivity and virus spread. The proteases HAT (human airway trypsin-like protease) and TMPRSS2 (transmembrane protease serine S1 member 2) known to be present in the human airways were previously identified as proteases that cleave HA. We studied subcellular localization of HA cleavage and cleavage inhibition of seasonal influenza virus A/Memphis/14/96 (H1N1) and pandemic virus A/Hamburg/5/ 2009 (H1N1) in MDCK cells that express HAT and TMPRSS2 under doxycycline-induced transcriptional activation. We made the following observations: (i) HA is cleaved by membrane-bound TMPRSS2 and HAT and not by soluble forms released into the supernatant; (ii) HAT cleaves newly synthesized HA before or during the release of progeny virions and HA of incoming viruses prior to endocytosis at the cell surface, whereas TMPRSS2 cleaves newly synthesized HA within the cell and is not able to support the proteolytic activation of HA of incoming virions; and (iii) cleavage activation of HA and virus spread in TMPRSS2-and HATexpressing cells can be suppressed by peptide mimetic protease inhibitors. The further development of these inhibitors could lead to new drugs for influenza treatment.Human influenza viruses cause acute infection of the respiratory tract that affects millions of people during seasonal outbreaks every year. Furthermore, the emergence of a new influenza virus for which there is little or no immunity in the human population may provoke an influenza pandemic, as is the case with the currently circulating swine origin H1N1 influenza A virus.Influenza virus replication is initiated by the surface glycoprotein hemagglutinin (HA) that mediates binding to sialic acid-containing cell surface receptors and fusion of the viral envelope with the endosomal membrane. HA is synthesized as a precursor protein HA0 and needs to be cleaved by a host cell protease into the subunits HA1 and HA2 to gain its fusion capacity (10,20,37). Proteolytic cleavage of HA0 enables HA to undergo conformational changes at low pH that expose the N-terminal hydrophobic fusion peptide of HA2 and trigger membrane fusion (36). HA0 of most avian and mammalian influenza viruses contains a single arginine, rarely a single lysine, at the cleavage site. In general, activation of HA0 with a monobasic cleavage site was assumed to occur extracellularly when virions are already released from the cells, and trypsin (21, 22), as well as several trypsin-like proteases such as plasmin (12, 23, 24), tryptase Clara from rat bronchiolar epithelial Clara cells, mast cell tryptase from porcine lung (19), and a protease similar to blood clotting factor Xa from chicken allantoic fluid (13), have been identified as HA-activating enzymes in vitro. Furthermore, some bacterial proteases were shown to support proteolytic activation of HA, too (32, 41). However, the proteases responsible for HA cleavage in the human airways were only poorly defined until recent...
Proprotein convertases (PCs) are highly specific proteases required for the proteolytic modification of many secreted proteins. An unbalanced activity of these enzymes is connected to pathologies like cancer, atherosclerosis, hypercholesterolaemia, and infectious diseases. Novel protein crystallographic structures of the prototypical PC family member furin in different functional states were determined to 1.8-2.0 Å. These, together with biochemical data and modeling by molecular dynamics calculations, suggest essential elements underlying its unusually high substrate specificity. Furin shows a complex activation mechanism and exists in at least four defined states: (i) the "off state," incompatible with substrate binding as seen in the unliganded enzyme; (ii) the active "on state" seen in inhibitor-bound furin; and the respective (iii) calcium-free and (iv) calcium-bound forms. The transition from the off to the on state is triggered by ligand binding at subsites S1 to S4 and appears to underlie the preferential recognition of the four-residue sequence motif of furin. The molecular dynamics simulations of the four structural states reflect the experimental observations in general and provide approximations of the respective stabilities. Ligation by calcium at the PC-specific binding site II influences the active-site geometry and determines the rotamer state of the oxyanion holeforming Asn295, and thus adds a second level of the activity modulation of furin. The described crystal forms and the observations of different defined functional states may foster the development of new tools and strategies for pharmacological intervention targeting furin.serine-protease | activation | specificity | conformational transition
New peptidomimetic furin inhibitors with unnatural amino acid residues in the P3 position were synthesized. The most potent compound 4-guanidinomethyl-phenylacteyl-Arg-Tle-Arg-4-amidinobenzylamide (MI-1148) inhibits furin with a Ki value of 5.5 pM. The derivatives also strongly inhibit PC1/3, whereas PC2 is less affected. Selected inhibitors were tested in cell culture for antibacterial and antiviral activity against infectious agents known to be dependent on furin activity. A significant protective effect against anthrax and diphtheria toxin was observed in the presence of the furin inhibitors. Furthermore, the spread of the highly pathogenic H5N1 and H7N1 avian influenza viruses and propagation of canine distemper virus was strongly inhibited. Inhibitor MI-1148 was crystallized in complex with human furin. Its N-terminal guanidinomethyl group in the para position of the P5 phenyl ring occupies the same position as that found previously for a structurally related inhibitor containing this substitution in the meta position, thereby maintaining all of the important P5 interactions. Our results confirm that the inhibition of furin is a promising strategy for a short-term treatment of acute infectious diseases.
Background: Furin and furin-like proprotein convertases are involved in disease-related processes and have emerged as potential drug targets. Results: The incorporation of basic acyl residues at P5 position provides highly potent inhibitors of furin, PC1/3, PC4, PACE4, and PC5/6. Conclusion: These inhibitors could be potential drugs for the treatment of infectious diseases. Significance: The most potent synthetic inhibitors of furin-like proprotein convertases have been developed.
Furin belongs to the family of proprotein convertases (PCs) and is involved in numerous normal physiological and pathogenic processes, such as viral propagation, bacterial toxin activation, cancer and metastasis. Furin and related furin-like PCs cleave their substrates at characteristic multibasic consensus sequences, preferentially after an arginine residue. By incorporation of decarboxylated arginine mimetics in P1 position of substrate analogue peptidic inhibitors we could identify highly potent furin inhibitors. The most potent compound, phenylacetyl-Arg-Val-Arg-4-amidinobenzylamide (15), inhibits furin with a K i -value of 0.81 nM and has also comparable affinity to other PCs like PC1/3, PACE4, and PC5/6, whereas PC2 and PC7 or trypsin-like serine proteases were poorly affected. In fowl plague virus (influenza A, H7N1)-infected MDCK cells inhibitor 15 reduced proteolytic hemagglutinin cleavage and was able to reduce virus propagation in a long term infection test. Molecular modelling revealed several key interactions of the 4-amidinobenzylamide residue in the S1 pocket of furin contributing to the excellent affinity of these inhibitors.
The serine protease urokinase-type plasminogen activator (uPA) interacts with a specific receptor (uPAR) on the surface of various cell types, including tumor cells, and plays a crucial role in pericellular proteolysis. High levels of uPA and uPAR often correlate with poor prognosis of cancer patients. Therefore, the specific inhibition of uPA with small molecule active-site inhibitors is one strategy to decrease the invasive and metastatic activity of tumor cells. We have developed a series of highly potent and selective uPA inhibitors with a C-terminal 4-amidinobenzylamide residue. Optimization was directed toward reducing the fast elimination from circulation that was observed with initial analogues. The x-ray structures of three inhibitor/uPA complexes have been solved and were used to improve the inhibition efficacy. One of the most potent and selective derivatives, benzylsulfonyl-D-SerSer-4-amidinobenzylamide (inhibitor 26), inhibits uPA with a K i of 20 nM. This inhibitor was used in a fibrosarcoma model in nude mice using lacZ-tagged human HT1080 cells, to prevent experimental lung metastasis formation. Compared with control (100%), an inhibitor dose of 2 ؋ 1.5 mg/kg/day reduced the number of experimental metastases to 4.6 ؎ 1%. Under these conditions inhibitor 26 also significantly prolonged survival. All mice from the control group died within 43 days after tumor cell inoculation, whereas 50% of mice from the inhibitor-treated group survived more than 117 days. This study demonstrates that the specific inhibition of uPA by these inhibitors may be a useful strategy for the treatment of cancer to prevent metastasis.The detachment of malignant cells from the primary tumor and their subsequent migration within the surrounding tissue, including intravasation and extravasation into blood and lymph vessels, leads to tumor dissemination and the formation of metastases at distant loci. Whereas a solid tumor can be removed by surgery or treated by radio-, chemo-, or hormone therapy, invasive tumor cells that have spread over the whole body can form secondary tumors leading to poor prognosis or death of cancer patients. Several proteases, such as matrix metalloproteases, the cysteine proteases cathepsin B and L, the aspartyl protease cathepsin D, and serine proteases, e.g. plasmin and uPA, 1 are involved at multiple stages during growth, invasion and progression of tumors, including metastases formation (1). High levels of expression of these proteases often correlate with poor prognosis for cancer patients (2). However, in several clinical cancer trials with different types of nonspecific matrix metalloprotease inhibitors, disappointing results with poor benefit and severe side effects were observed (3). This stimulated the search for alternative proteases with matrix degrading activity as new targets for anti-cancer drugs. An important role in metastasis has been recently ascribed to the plasmin-plasminogen activation system and especially to uPA.Both, uPA and the second endogenous plasminogen activator tPA are...
Furin inhibitors are promising therapeutics for the treatment of cancer and numerous infections caused by bacteria and viruses, including the highly lethal Bacillus anthracis or the pandemic influenza virus. Development and improvement of inhibitors for pharmacological use require a detailed knowledge of the protease’s substrate and inhibitor binding properties. Here we present a novel preparation of human furin and the first crystal structures of this enzyme in complex with noncovalent inhibitors. We show the inhibitor exchange by soaking, allowing the investigation of additional inhibitors and substrate analogues. Thus, our work provides a basis for the rational design of furin inhibitors.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.